Evidence map›Paper›PMID 41872852›Full record

ArticleJournal of nanobiotechnology2026

Oral colon targeted curcumin-based nanocomposite inulin hydrogel for alleviating intestinal inflammation and dysbiosis.

Qiangyuan Fan, Chen Kan, Kesheng Wang, Huanhuan Zhu, Yue Zhang, Meiling Lu, Shaobo Xue, Lin Han, Zhongmin Geng, Weiliang Hou and 1 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Journal of nanobiotechnology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors.

Qiangyuan Fan *Central Laboratory, Shanghai Tenth People's Hospital, School of Medicine, Tongji University, Shanghai, 200092, China.
Chen Kan *Central Laboratory, Shanghai Tenth People's Hospital, School of Medicine, Tongji University, Shanghai, 200092, China.
Kesheng WangCentral Laboratory, Shanghai Tenth People's Hospital, School of Medicine, Tongji University, Shanghai, 200092, China.
Huanhuan ZhuCentral Laboratory, Shanghai Tenth People's Hospital, School of Medicine, Tongji University, Shanghai, 200092, China.
Yue ZhangCentral Laboratory, Shanghai Tenth People's Hospital, School of Medicine, Tongji University, Shanghai, 200092, China.
Meiling LuCentral Laboratory, Shanghai Tenth People's Hospital, School of Medicine, Tongji University, Shanghai, 200092, China.
Shaobo XueCentral Laboratory, Shanghai Tenth People's Hospital, School of Medicine, Tongji University, Shanghai, 200092, China.
Lin HanCentral Laboratory, Shanghai Tenth People's Hospital, School of Medicine, Tongji University, Shanghai, 200092, China.
Zhongmin GengCancer Institute, The Affiliated Hospital of Qingdao University, Qingdao University, Qingdao, 266071, China. gzmin-qdu@qdu.edu.cn.
Weiliang HouDepartment of Gastroenterology, Shanghai Institute of Pancreatic Diseases, National Key Laboratory of Immunity and Inflammation, Changhai Clinical Research Unit, Changhai Hospital, Naval Medical University, Shanghai, 200433, China. houweiliang@tongji.edu.cn.
Zunzhen MingSchool of Life Sciences, Shanghai University, Shanghai, 200444, China. mingzunzhen@shu.edu.cn.

Funding

Fundamental Research Funds for the Central Universities No. 22120240344National Natural Science Foundation of China No. 32201079Shanghai Municipal Health Commission No. 20244Y0224
6 · The paper itself

Abstract

Scavenging excess reactive oxygen species (ROS) and positively improving intestinal dysbiosis is a promising therapeutic strategy for alleviating inflammatory bowel disease (IBD). However, conventional clinical drugs and probiotic-based adjuvant therapies often fail to achieve satisfactory results due to systemic side effects of drugs, low bioactivity of probiotics, short intestinal retention time, and poor targeting ability. To address these challenges, we developed an antioxidant-functionalized curcumin loaded nanocomposite inulin hydrogel for targeted IBD therapy. In this system, curcumin was encapsulated within chitosan-coated Poly (lactic-co-glycolic acid) PLGA nanoparticles, which not only exhibited excellent ROS-scavenging capacity but also demonstrated the enhanced cellular uptake behavior. In a dextran sulfate sodium induced ulcerative colitis mouse model, the nanocomposite hydrogel significantly prolonged the intestinal retention time of curcumin, thereby suppressing the expression of pro-inflammatory factors, alleviating intestinal inflammation, and promoting the recovery of intestinal barrier and microbial diversity. This study has developed a synergistic therapeutic strategy via combining anti-inflammatory effects with gut microbiota regulation, offering a novel therapeutic approach for the clinical management of colitis.

Indexed as

ColonCurcuminDysbiosisHydrogelsInulinNanocompositesAdministration, OralAnimalsAnti-Inflammatory AgentsAntioxidantsChitosanColitis, UlcerativeDextran SulfateDisease Models, AnimalGastrointestinal MicrobiomeHumansAnti-Inflammatory AgentsAntioxidantsChitosanCurcuminDextran SulfateHydrogelsInulinPolylactic Acid-Polyglycolic Acid CopolymerReactive Oxygen Speciescolon targetedCurcumininflammatory bowel diseaseinulin hydrogeloral administration

Identifiers

PMID41872852
PMCPMC13134146

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.